Cytosorbents vs Electrocore
Cytosorbents is the larger business, with $37.1m of revenue in fiscal 2025 against $32.0m for Electrocore (1.2 times as much). Electrocore grew faster (27.2% against 4.1%). Cytosorbents kept more of each dollar of sales as profit: a net margin of -22.1% against -43.6%.
| Latest fiscal year | CytosorbentsCTSO, 2025 | ElectrocoreECOR, 2025 |
|---|---|---|
| Revenue | $37.1m | $32.0m |
| Revenue growth | 4.1% | 27.2% |
| Net income | −$8.2m | −$14.0m |
| Operating margin | -39.8% | -41.1% |
| Net margin | -22.1% | -43.6% |
| Return on equity | -96.4% | — |
| Free cash flow | −$12.5m | −$8.3m |
| Cash | $6.2m | $7.0m |
| Total debt | $18.4m | $7.8m |
| Debt to equity | 311.7% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 129 | 83 |
| Market value | $259m | $64.5m |
| Price vs our value range | — | — |
| Moat score | 28 (Weak) | 37 (Weak) |
| Insider trades, 12 months | 10 buys, 0 sales | 5 buys, 9 sales |